Transarterial chemoembolization combined with apatinib in the treatment of advanced hepatocellular carcinoma: a prospective, multi-center, real-world study (Ahend-HAP02)
PurposeTo analyze the efficacy and safety of transarterial chemoembolization (TACE) with apatinib (TACE-A) for the treatment of advanced hepatocellular carcinoma (HCC).MethodsData from advanced HCC patients treated with TACE-A between January 2019 and June 2022 were evaluated. The patients from 8 me...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1615911/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839640694529982464 |
|---|---|
| author | Hang Yuan Zhen Li Guang-Shao Cao Fei Xu Gang Wu Peng-Xu Ding Qiu-Liang Wei Zu-Kuan Chang Cheng Xing Huan-Zhang Niu Jun Yin Quan-Jun Yao Lin Zheng Jin-Cheng Xiao Cheng-Shi Chen Hong-Tao Cheng Deng-Wei Zong Wei-Li Xia Xiang Geng Xiao-Hui Zhao Hai-Liang Li Hong-Tao Hu |
| author_facet | Hang Yuan Zhen Li Guang-Shao Cao Fei Xu Gang Wu Peng-Xu Ding Qiu-Liang Wei Zu-Kuan Chang Cheng Xing Huan-Zhang Niu Jun Yin Quan-Jun Yao Lin Zheng Jin-Cheng Xiao Cheng-Shi Chen Hong-Tao Cheng Deng-Wei Zong Wei-Li Xia Xiang Geng Xiao-Hui Zhao Hai-Liang Li Hong-Tao Hu |
| author_sort | Hang Yuan |
| collection | DOAJ |
| description | PurposeTo analyze the efficacy and safety of transarterial chemoembolization (TACE) with apatinib (TACE-A) for the treatment of advanced hepatocellular carcinoma (HCC).MethodsData from advanced HCC patients treated with TACE-A between January 2019 and June 2022 were evaluated. The patients from 8 medical centers were included. The primary endpoints were overall survival (OS) and progression-free survival (PFS). The secondary endpoints were objective response rate (ORR) and adverse events (AEs). Prognostic factors affecting OS were analyzed, and the tumor imaging response at the first follow-up was evaluated to study the survival differences among patients.ResultsA total of 389 patients were included, the median PFS was 7.0 months (95% confidence interval [CI]: 6.3–7.7), and the median OS (mOS) was 18.9 months (95% CI: 17.5–20.3). The median time of the first follow-up was 1.2 months, the ORR was 33.7%, and the mOS of the complete response, partial response, stable disease, and progressive disease groups were 30.1, 20.9, 18.5, and 12.9 months, respectively. The difference was statistically significant (p < 0.05). Univariate and multivariate Cox regression analyses demonstrated that the prognostic factors affecting OS were distant metastasis, maximum tumor diameter, TACE duration, and alpha-fetoprotein (AFP) level (p < 0.05). The overall incidence of grade 3 and above AEs was 18.0% (70/389), and the overall safety was controllable.ConclusionTACE-A significantly improved OS, PFS, and ORR in advanced HCC patients. At the first follow-up patients with a poor tumor response had a poor prognosis. Distant metastasis, maximum tumor diameter, TACE frequency, and AFP levels are important prognostic factors that affect OS in patients. AEs of combination therapy are safe and manageable.Clinical trial numberChinese Clinical Trials Database (ChiCTR1900024030). |
| format | Article |
| id | doaj-art-b3dd924fc52044e1b92e60e28d75c8f4 |
| institution | Matheson Library |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-b3dd924fc52044e1b92e60e28d75c8f42025-07-03T09:51:07ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-07-011510.3389/fonc.2025.16159111615911Transarterial chemoembolization combined with apatinib in the treatment of advanced hepatocellular carcinoma: a prospective, multi-center, real-world study (Ahend-HAP02)Hang Yuan0Zhen Li1Guang-Shao Cao2Fei Xu3Gang Wu4Peng-Xu Ding5Qiu-Liang Wei6Zu-Kuan Chang7Cheng Xing8Huan-Zhang Niu9Jun Yin10Quan-Jun Yao11Lin Zheng12Jin-Cheng Xiao13Cheng-Shi Chen14Hong-Tao Cheng15Deng-Wei Zong16Wei-Li Xia17Xiang Geng18Xiao-Hui Zhao19Hai-Liang Li20Hong-Tao Hu21Department of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Intervention, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, ChinaDepartment of Minimal-Invasive Intervention, Anyang Tumor Hospital/The Forth Affiliated Hospital of Henan University of Science and Technology, Anyang, ChinaDepartment of Interventional Therapy, Xinxiang Central Hospital/the Fourth Clinical College of Xinxiang Medical University, Xinxiang, ChinaDepartment of Interventional Therapy, Zhoukou Central Hospital, Zhoukou, ChinaDepartment of lnterventional Radiology, The First Afiliated Hospital of Henan Science and Techology University, Luoyang, ChinaDepartment of lnterventional Radiology, Xinyang Central Hospital, Xinyang, ChinaDepartment of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China0Department of Interventional Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, ChinaDepartment of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, ChinaPurposeTo analyze the efficacy and safety of transarterial chemoembolization (TACE) with apatinib (TACE-A) for the treatment of advanced hepatocellular carcinoma (HCC).MethodsData from advanced HCC patients treated with TACE-A between January 2019 and June 2022 were evaluated. The patients from 8 medical centers were included. The primary endpoints were overall survival (OS) and progression-free survival (PFS). The secondary endpoints were objective response rate (ORR) and adverse events (AEs). Prognostic factors affecting OS were analyzed, and the tumor imaging response at the first follow-up was evaluated to study the survival differences among patients.ResultsA total of 389 patients were included, the median PFS was 7.0 months (95% confidence interval [CI]: 6.3–7.7), and the median OS (mOS) was 18.9 months (95% CI: 17.5–20.3). The median time of the first follow-up was 1.2 months, the ORR was 33.7%, and the mOS of the complete response, partial response, stable disease, and progressive disease groups were 30.1, 20.9, 18.5, and 12.9 months, respectively. The difference was statistically significant (p < 0.05). Univariate and multivariate Cox regression analyses demonstrated that the prognostic factors affecting OS were distant metastasis, maximum tumor diameter, TACE duration, and alpha-fetoprotein (AFP) level (p < 0.05). The overall incidence of grade 3 and above AEs was 18.0% (70/389), and the overall safety was controllable.ConclusionTACE-A significantly improved OS, PFS, and ORR in advanced HCC patients. At the first follow-up patients with a poor tumor response had a poor prognosis. Distant metastasis, maximum tumor diameter, TACE frequency, and AFP levels are important prognostic factors that affect OS in patients. AEs of combination therapy are safe and manageable.Clinical trial numberChinese Clinical Trials Database (ChiCTR1900024030).https://www.frontiersin.org/articles/10.3389/fonc.2025.1615911/fulltransarterial chemoembolizationapatinibhepatocellular carcinomareal worldoverall survival |
| spellingShingle | Hang Yuan Zhen Li Guang-Shao Cao Fei Xu Gang Wu Peng-Xu Ding Qiu-Liang Wei Zu-Kuan Chang Cheng Xing Huan-Zhang Niu Jun Yin Quan-Jun Yao Lin Zheng Jin-Cheng Xiao Cheng-Shi Chen Hong-Tao Cheng Deng-Wei Zong Wei-Li Xia Xiang Geng Xiao-Hui Zhao Hai-Liang Li Hong-Tao Hu Transarterial chemoembolization combined with apatinib in the treatment of advanced hepatocellular carcinoma: a prospective, multi-center, real-world study (Ahend-HAP02) Frontiers in Oncology transarterial chemoembolization apatinib hepatocellular carcinoma real world overall survival |
| title | Transarterial chemoembolization combined with apatinib in the treatment of advanced hepatocellular carcinoma: a prospective, multi-center, real-world study (Ahend-HAP02) |
| title_full | Transarterial chemoembolization combined with apatinib in the treatment of advanced hepatocellular carcinoma: a prospective, multi-center, real-world study (Ahend-HAP02) |
| title_fullStr | Transarterial chemoembolization combined with apatinib in the treatment of advanced hepatocellular carcinoma: a prospective, multi-center, real-world study (Ahend-HAP02) |
| title_full_unstemmed | Transarterial chemoembolization combined with apatinib in the treatment of advanced hepatocellular carcinoma: a prospective, multi-center, real-world study (Ahend-HAP02) |
| title_short | Transarterial chemoembolization combined with apatinib in the treatment of advanced hepatocellular carcinoma: a prospective, multi-center, real-world study (Ahend-HAP02) |
| title_sort | transarterial chemoembolization combined with apatinib in the treatment of advanced hepatocellular carcinoma a prospective multi center real world study ahend hap02 |
| topic | transarterial chemoembolization apatinib hepatocellular carcinoma real world overall survival |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1615911/full |
| work_keys_str_mv | AT hangyuan transarterialchemoembolizationcombinedwithapatinibinthetreatmentofadvancedhepatocellularcarcinomaaprospectivemulticenterrealworldstudyahendhap02 AT zhenli transarterialchemoembolizationcombinedwithapatinibinthetreatmentofadvancedhepatocellularcarcinomaaprospectivemulticenterrealworldstudyahendhap02 AT guangshaocao transarterialchemoembolizationcombinedwithapatinibinthetreatmentofadvancedhepatocellularcarcinomaaprospectivemulticenterrealworldstudyahendhap02 AT feixu transarterialchemoembolizationcombinedwithapatinibinthetreatmentofadvancedhepatocellularcarcinomaaprospectivemulticenterrealworldstudyahendhap02 AT gangwu transarterialchemoembolizationcombinedwithapatinibinthetreatmentofadvancedhepatocellularcarcinomaaprospectivemulticenterrealworldstudyahendhap02 AT pengxuding transarterialchemoembolizationcombinedwithapatinibinthetreatmentofadvancedhepatocellularcarcinomaaprospectivemulticenterrealworldstudyahendhap02 AT qiuliangwei transarterialchemoembolizationcombinedwithapatinibinthetreatmentofadvancedhepatocellularcarcinomaaprospectivemulticenterrealworldstudyahendhap02 AT zukuanchang transarterialchemoembolizationcombinedwithapatinibinthetreatmentofadvancedhepatocellularcarcinomaaprospectivemulticenterrealworldstudyahendhap02 AT chengxing transarterialchemoembolizationcombinedwithapatinibinthetreatmentofadvancedhepatocellularcarcinomaaprospectivemulticenterrealworldstudyahendhap02 AT huanzhangniu transarterialchemoembolizationcombinedwithapatinibinthetreatmentofadvancedhepatocellularcarcinomaaprospectivemulticenterrealworldstudyahendhap02 AT junyin transarterialchemoembolizationcombinedwithapatinibinthetreatmentofadvancedhepatocellularcarcinomaaprospectivemulticenterrealworldstudyahendhap02 AT quanjunyao transarterialchemoembolizationcombinedwithapatinibinthetreatmentofadvancedhepatocellularcarcinomaaprospectivemulticenterrealworldstudyahendhap02 AT linzheng transarterialchemoembolizationcombinedwithapatinibinthetreatmentofadvancedhepatocellularcarcinomaaprospectivemulticenterrealworldstudyahendhap02 AT jinchengxiao transarterialchemoembolizationcombinedwithapatinibinthetreatmentofadvancedhepatocellularcarcinomaaprospectivemulticenterrealworldstudyahendhap02 AT chengshichen transarterialchemoembolizationcombinedwithapatinibinthetreatmentofadvancedhepatocellularcarcinomaaprospectivemulticenterrealworldstudyahendhap02 AT hongtaocheng transarterialchemoembolizationcombinedwithapatinibinthetreatmentofadvancedhepatocellularcarcinomaaprospectivemulticenterrealworldstudyahendhap02 AT dengweizong transarterialchemoembolizationcombinedwithapatinibinthetreatmentofadvancedhepatocellularcarcinomaaprospectivemulticenterrealworldstudyahendhap02 AT weilixia transarterialchemoembolizationcombinedwithapatinibinthetreatmentofadvancedhepatocellularcarcinomaaprospectivemulticenterrealworldstudyahendhap02 AT xianggeng transarterialchemoembolizationcombinedwithapatinibinthetreatmentofadvancedhepatocellularcarcinomaaprospectivemulticenterrealworldstudyahendhap02 AT xiaohuizhao transarterialchemoembolizationcombinedwithapatinibinthetreatmentofadvancedhepatocellularcarcinomaaprospectivemulticenterrealworldstudyahendhap02 AT hailiangli transarterialchemoembolizationcombinedwithapatinibinthetreatmentofadvancedhepatocellularcarcinomaaprospectivemulticenterrealworldstudyahendhap02 AT hongtaohu transarterialchemoembolizationcombinedwithapatinibinthetreatmentofadvancedhepatocellularcarcinomaaprospectivemulticenterrealworldstudyahendhap02 |